A class action lawsuit has been filed against Zoetis Inc. alleging the company misled investors about the strength of its Companion Animal segment. The lawsuit claims Zoetis portrayed this segment as a strong growth driver while hiding safety concerns, rising competition, and declining veterinarian confidence that hurt sales and outlook. The truth emerged through disclosures from August 2025 to May 2026, culminating in a sharp stock price drop of 21.5% after poor Q1 2026 results and lowered guidance. Investors who bought Zoetis shares between January 2025 and May 2026 are encouraged to contact the law firm before the July 27, 2026 deadline to participate in the case.
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud and other unlawful practices following the company's announcement of a profit guidance cut for 2026. Zoetis reported flat net income of $601 million for Q1 ...
Pomerantz LLP has filed a class action lawsuit against Zoetis Inc., alleging securities fraud linked to the company's lowered 2026 profit guidance and a significant stock price drop. Zoetis reported flat net income for Q1 2026 and reduced its full-ye...
Zoetis, once a high-performing stock, has fallen about 70% from its peak in December 2021, mainly because its U.S. companion animal business saw an 11% organic decline in Q1 2026 after strong growth in 2021. The decline is linked to weaker U.S. consu...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by rising demand for rapid diagnostics, AI integration, and precision veterinary medicine, alongside i...
The veterinary lab automation market is projected to grow from $1.36 billion in 2026 to $1.9 billion by 2030, with a CAGR of 8.7%. Growth is fueled by increasing demand for rapid diagnostics, AI integration, robotic workflows, and a focus on companio...
